ライフサイエンスコーパス: varicella

1 r healthy individuals who are susceptible to varicella.

2 done in ten European countries with endemic varicella.

3 , 3.9 months for rubella, and 3.4 months for varicella.

4 caused dramatic declines in the incidence of varicella.

5 , a neurotropic alphaherpesvirus, results in varicella.

6 in the risk of scabies, dermatophytosis and varicella.

7 ytial virus (7.5 days), measles (11.7 days), varicella (14.0 days), smallpox (17.7 days), mumps (18.0

8 aricella-zoster virus (VZV) infection causes varicella, after which the virus becomes latent in gangl

9 ractions in the sensory ganglia during acute varicella and demonstrate that SVV infection results in

10 virus (VZV) is a highly contagious agent of varicella and herpes zoster.

11 Zoster Virus (VZV) is the causative agent of varicella and herpes zoster.

12 the impact of mass immunization programs for varicella and therefore extends the range of tools avail

13 Despite the lack of varicella and viral replication in either the lungs or w

14 nial nerve ganglia during primary infection (varicella), and the virus can reactivate and cause zoste

15 ed participants' most recent stored sera for varicella antibody using whole-cell and glycoprotein enz

16 have observed a 70% reduction in the rate of varicella-associated invasive group A streptococcal infe

17 fficacy endpoint was occurrence of confirmed varicella (by detection of varicella zoster virus DNA or

18 Varicella can be lethal to immunocompromised patients, b

19 A varicella case was considered to be sporadic if it was r

20 Of 1358 sporadic varicella cases reported, 205 (15%) resulted in 564 seco

21 Approximately half of the HZ and sporadic varicella cases resulted in single secondary cases.

22 Varicella cases were confirmed for 37 participants in th

23 Varicella cases were moderate to severe for two particip

24 eported, 205 (15%) resulted in 564 secondary varicella cases.

25 s reported, 27 (9%) resulted in 84 secondary varicella cases.

26 ster virus (VZV) is the etiological agent of varicella (chickenpox) and herpes zoster (HZ [shingles])

27 r virus (VZV) is the causative agent of both varicella (chickenpox) and herpes zoster (HZ) (shingles)

28 lphaherpesvirus and the etiological agent of varicella (chickenpox) and herpes zoster (HZ, shingles).

29 ster virus (VZV) is the etiological agent of varicella (chickenpox) and herpes zoster (shingles).

30 VZV causes varicella (chickenpox), becomes latent in ganglia, and r

31 dult siblings with a history of disseminated varicella, cutaneous warts, and CD4(+) T-cell lymphopeni

32 ensure optimum protection from all forms of varicella disease.

33 strain Oka is attenuated, it can cause mild varicella, establish latency, and in rare cases, reactiv

34 Rates of varicella have decreased substantially in countries impl

35 Exposure of varicella-immune persons to VZV may boost the host's imm

36 ll the hallmarks of VZV infection, including varicella, immunity, latency, and reactivation.

37 age 2 years of measles, mumps, rubella, and varicella immunization may offer improved disease contro

38 modeling approaches regarding the effect of varicella immunization on HZ.

39 pathogenesis is required before further mass varicella immunization programs are set out.

40 V), of the family Alphaherpesvirinae, causes varicella in children and young adults, potentially lead

41 We assessed protection against varicella in naive children administered one dose of var

42 us, is associated with seasonal outbreaks of varicella in nonimmunized populations.

43 ment, such as allergy, immunoglobulin E, and Varicella infection status.

44 After varicella infection, the virus remains dormant in the ho

45 d hypogammaglobulinemia; one also had severe varicella infection.

46 erentiation of the disease from smallpox and varicella is difficult.

47 her in respiratory droplets or from shedding varicella lesions or by direct contact with infectious v

48 ving treatment excluding doxorubicin died of varicella, metabolic seizure, and sepsis during treatmen

49 mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccine was assessed in children born t

50 vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunization schedules sh

51 hin the subsequent 42 days, no case of HZ or varicella occurred.

52 aged 50 years or older who had a history of varicella or who had resided in a country with endemic v

53 s, 11 of 16 positive controls with zoster or varicella (P < .0001), 2 of 2 patients with zoster sine

54 from unvaccinated individuals with sporadic varicella (P < .01).

55 (57.2-72.1), and against moderate to severe varicella (post hoc) was 90.7% (85.9-93.9).

56 VZV-immune RMs displayed no varicella rash and had lower SVV viral loads and earlier

57 Varicella severity and viral latency within sensory gang

58 rus (VZV) is an alphaherpesvirus that causes varicella upon primary infection and zoster upon reactiv

59 to 2010, HZ incidence did not vary by state varicella vaccination coverage (RR, 0.9998 [CI, 0.9993 t

60 sex, and race or ethnicity; and state-level varicella vaccination coverage.

61 sults support the implementation of two-dose varicella vaccination on a short course, to ensure optim

62 The impact of varicella vaccination on the epidemiology of herpes zost

63 tes before and after the introduction of the varicella vaccination program.

64 even before implementation of the childhood varicella vaccination program.

65 e rate of increase after introduction of the varicella vaccination program.

66 ease before vs after the introduction of the varicella vaccination program.

67 is unlikely to be due to the introduction of varicella vaccination, antiviral therapy, or change in t

68 stantially in countries implementing routine varicella vaccination.

69 assuring for countries considering universal varicella vaccination.

70 ne-strain herpes zoster (HZ) can occur after varicella vaccination.

71 vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).

72 The live attenuated Oka varicella vaccine (vOka), derived from clade 2 wild-type

73 Efficacy of one-dose varicella vaccine against all varicella was 65.4% (57.2-

74 Humoral immune responses to varicella vaccine are best achieved when children with P

75 roup), or (2) MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group), or (3) two

76 as associated with a 4.0% increase in 1-dose varicella vaccine coverage.

77 rubella vaccine administered with or without varicella vaccine in both younger and older children.

78 The Oka/Merck varicella vaccine induces VZV immunity in elderly nursin

79 The combination measles, mumps, rubella, and varicella vaccine is associated with a 2-fold increased

80 The current varicella vaccine is highly attenuated in the skin and y

81 Live attenuated varicella vaccine is recommended for healthy individuals

82 Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella-va

83 a in naive children administered one dose of varicella vaccine or two doses of MMRV.

84 Introduction of a universal varicella vaccine program for U.S. children in 1996 spar

85 were stratified by age: less than 20 years (varicella vaccine recommended), 20 to 59 years (no vacci

86 The live, attenuated varicella vaccine strain (vOka) is the only licensed the

87 Since the introduction of the varicella vaccine to the routine immunization schedule,

88 f vaccine type, measles, mumps, rubella, and varicella vaccine was associated with a 1.4-fold increas

89 virus (VZV)-containing vaccine (hereafter, "varicella vaccine") in frail nursing homes residents nor

90 accine uptake for 2-dose MCV and single-dose varicella vaccine, focusing on timeliness.

91 Despite no change in the scheduled age of varicella vaccine, use of MMRV vaccine was associated wi

92 the strain carried 15 of 42 (36%) recognized varicella vaccine-associated single-nucleotide polymorph

93 n immunocompromised patient who received the varicella vaccine.

94 ed 60-75 years (a comparison group) received varicella vaccine.

95 and rubella and measles, mumps, rubella, and varicella vaccines among children who are 1 year of age.

96 administered measles, mumps, and rubella and varicella vaccines.

97 anese encephalitis virus (JEV) (SA-14-14-2), varicella (Varivax), measles, mumps, and rubella (MMR-II

98 rred partial cross-protection against simian varicella virus (SVV) challenge.

99 Simian varicella virus (SVV) infection of rhesus macaques (RMs)

100 Simian varicella virus (SVV) infection of rhesus macaques recap

101 Since infection of rhesus macaques by simian varicella virus (SVV) is used as an animal model of VZV

102 Like varicella-zoster virus (VZV), simian varicella virus (SVV) reactivates to produce zoster.

103 sus macaques (RM) with the homologous simian varicella virus (SVV) recapitulates hallmarks of VZV inf

104 l inoculation of rhesus macaques with simian varicella virus (SVV) recapitulates the hallmarks of VZV

105 Infection of rhesus macaques with simian varicella virus (SVV), a homolog of VZV, provides a robu

106 l inoculation of rhesus macaques with simian varicella virus (SVV), a homolog of VZV, recapitulates t

107 ulation of young rhesus macaques with simian varicella virus (SVV), a homolog of VZV, recapitulates t

108 ulation of rhesus macaques (RMs) with simian varicella virus (SVV), a homolog of VZV, recapitulates v

109 y challenged with the closely related Simian Varicella Virus (SVV).

110 he importance of these countermechanisms for varicella virus infection.

111 ion of the host response required to control varicella virus replication in the lung and provide insi

112 to study how increasing the vulnerability of varicella viruses to innate immunity will impact viral p

113 cy of one-dose varicella vaccine against all varicella was 65.4% (57.2-72.1), and against moderate to

114 Efficacy of two-dose MMRV against all varicella was 94.9% (97.5% CI 92.4-96.6), and against mo

115 I 92.4-96.6), and against moderate to severe varicella was 99.5% (97.5-99.9).

116 For varicella, we found an evidence-based value that deviate

117 events for some outcomes such as scabies or varicella, which may have led to limited statistical pow

118 arked concern that less-frequent exposure to varicella would decrease external boosting of immunity t

119 of herpes zoster disease, which is caused by Varicella zoster Nevertheless, the pathophysiological me

120 laria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III).

121 = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

122 s HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytome

123 Varicella zoster virus (VZV) and the two herpes simplex

124 Varicella zoster virus (VZV) antibody titers (measured b

125 Varicella zoster virus (VZV) antigen was found in all of

126 CMV and varicella zoster virus (VZV) are significant causes of m

127 response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzym

128 lex virus types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain

129 se of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a

130 Varicella zoster virus (VZV) establishes latency in dors

131 Varicella zoster virus (VZV) establishes lifelong persis

132 as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and further char

133 s positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of

134 Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovere

135 Reactivation of the varicella zoster virus (VZV) increases during aging.

136 Varicella zoster virus (VZV) infections are a relevant c

137 virus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored i

138 Varicella zoster virus (VZV) is a neurotropic alphaherpe

139 Varicella Zoster Virus (VZV) is the causative agent of v

140 Varicella zoster virus (VZV) is the etiological agent of

141 Varicella zoster virus (VZV) reactivation results in zos

142 An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being de

143 Varicella zoster virus (VZV) typically causes chickenpox

144 ne responses to a high-titer live attenuated varicella zoster virus (VZV) vaccine (zoster vaccine), w

145 s, granulomatous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

146 portion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed the positive pred

147 c primers to detect DNA from JC virus (JCV), varicella zoster virus (VZV), cytomegalovirus (CMV), Eps

148 on childhood disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

149 immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereaft

150 Boost of varicella zoster virus (VZV)-specific cellular immunity

151 We investigated the relationship between varicella zoster virus (VZV)-specific memory CD4(+) T ce

152 ses with age, which leads to reactivation of varicella zoster virus (VZV).

153 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV).

154 For herpes simplex virus, varicella zoster virus and cytomegalovirus, these advanc

155 RN, PCR-positive for herpes simplex virus or varicella zoster virus and evaluated between January 200

156 beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

157 ld decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of

158 ence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from

159 were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy

160 cation) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95

161 contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, a

162 processes, including ubiquitin clearance and Varicella Zoster Virus infection.

163 nd increased susceptibility to bacterial and varicella zoster virus infections.

164 One patient with varicella zoster virus meningitis and acute GVHD had iC9

165 -Barr virus, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex

166 ty of herpes simplex virus, cytomegalovirus, varicella zoster virus, and Epstein-Barr virus in our po

167 Herpes simplex virus, varicella zoster virus, and pseudorabies virus are neuro

168 nstrate that childhood infections, including varicella zoster virus, are associated with an increased

169 for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections)

170 itis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of

171 se encephalitis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus an

172 deficiency virus (HIV)-herpes simplex virus, varicella zoster virus, Epstein-Barr virus (EBV), and cy

173 gnificant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epste

174 genes, Treponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and He

175 highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinica

176 2, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus.

177 ew mutations or recombination with wild-type Varicella zoster virus.

178 ese is also activated by the closely related varicella zoster virus.

179 reaction (PCR) analysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus an

180 roidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoi

181 prophylaxis against Pneumocystis carinii and varicella zoster.

182 and pneumonia, and an increase observed for varicella zoster.

183 varicella-zoster virus vaccine in preventing varicella-zoster and herpes zoster is well documented, a

184 number and critical immunization coverage of varicella-zoster infection in Belgium, Italy, Poland, an

185 clonal expansions in response to attenuated varicella-zoster vaccination in four pairs of adult iden

186 Two doses of live-attenuated varicella-zoster vaccine are recommended for human immun

187 thy, such as prior herpes simplex keratitis, varicella-zoster viral keratitis, the linear form of Thy

188 1), P. jirovecii pneumonia (1.77; .42-7.47), varicella-zoster virus (1.51; .71-3.22), as well as over

189 Varicella-zoster virus (VZV) activates the phosphatidyli

190 SV functioned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjace

191 are the main architectural contrasts between varicella-zoster virus (VZV) and herpes simplex virus (H

192 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infe

193 gument proteins encoded by ORF11 and ORF9 of varicella-zoster virus (VZV) are conserved among all alp

194 Infection of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of in

195 Varicella-zoster virus (VZV) causes chickenpox and react

196 highly infectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shing

197 ating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shing

198 Varicella-zoster virus (VZV) causes chickenpox upon prim

199 Varicella-zoster virus (VZV) characteristically forms mu

200 Herein we describe an episode of focal varicella-zoster virus (VZV) encephalitis in a healthy y

201 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong late

202 Varicella-zoster virus (VZV) establishes latency in huma

203 ts had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measu

204 tive target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of pe

205 Mechanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to st

206 ects immediate-early protein IE63 encoded by varicella-zoster virus (VZV) in the cytoplasm of product

207 Varicella-zoster virus (VZV) induces apoptosis in human

208 Previous studies have demonstrated that varicella-zoster virus (VZV) infection activates ERK1/2,

209 Varicella-zoster virus (VZV) infection causes varicella,

210 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human

211 acaques (RMs) recapitulates the hallmarks of varicella-zoster virus (VZV) infection of humans, includ

212 Varicella-zoster virus (VZV) infection provides a valuab

213 extensively studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observe

214 Varicella-zoster virus (VZV) infections increasingly are

215 Varicella-zoster virus (VZV) is a common pathogen that c

216 Varicella-zoster virus (VZV) is a highly contagious agen

217 Varicella-zoster virus (VZV) is a highly neurotropic vir

218 Varicella-zoster virus (VZV) is a human neurotropic alph

219 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-acti

220 Varicella-zoster virus (VZV) is a ubiquitous pathogen th

221 Varicella-zoster virus (VZV) is a ubiquitous, highly cel

222 Varicella-zoster virus (VZV) is an alphaherpesvirus that

223 Varicella-zoster virus (VZV) is an extremely cell-associ

224 Varicella-zoster virus (VZV) is highly cell associated w

225 mary infection, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

226 Varicella-zoster virus (VZV) is the causative agent of b

227 Varicella-zoster virus (VZV) is the causative agent of c

228 Varicella-zoster virus (VZV) is the etiological agent of

229 We report a case of AIDS presenting as varicella-zoster virus (VZV) meningomyeloradiculitis ass

230 f herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneou

231 The varicella-zoster virus (VZV) open reading frame 54 (ORF5

232 Three loci in varicella-zoster virus (VZV) open reading frame 62 (ORF6

233 The varicella-zoster virus (VZV) ORF61 protein is necessary

234 ced syncytium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and senso

235 IMPORTANCE The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly ma

236 Varicella-zoster virus (VZV) T-cell responses by interfe

237 Varicella-zoster virus (VZV) T-cell-mediated immunity (V

238 The varicella-zoster virus (VZV) terminase components (pORF2

239 r herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by usi

240 Studies of varicella-zoster virus (VZV) tropism for T cells support

241 Although a varicella-zoster virus (VZV) vaccine has been used for m

242 75 years) immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

243 Varicella-zoster virus (VZV) vasculopathy produces strok

244 Varicella-zoster virus (VZV), a double-stranded DNA alph

245 igated during the entire infectious cycle of varicella-zoster virus (VZV), a human herpesvirus.

246 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activa

247 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesv

248 Regulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotr

249 pear healthy at 2 weeks after infection with varicella-zoster virus (VZV), and the cell culture mediu

250 ovirus, herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).

251 ults for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or

252 In this study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HS

253 Varicella-zoster virus (VZV), of the family Alphaherpesv

254 showed cytopathic changes, but HSV-1, unlike varicella-zoster virus (VZV), only rarely infected satel

255 Like varicella-zoster virus (VZV), simian varicella virus (SV

256 In varicella-zoster virus (VZV)-infected primary human brai

257 the risk of herpes zoster (HZ), we compared varicella-zoster virus (VZV)-specific and nonspecific T-

258 To measure varicella-zoster virus (VZV)-specific immune responses u

259 itive GCA is associated with TA infection by varicella-zoster virus (VZV).

260 rus (CMV), herpes simplex viruses (HSV), and varicella-zoster virus (VZV).

261 rpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV).

262 lication that can occur with reactivation of varicella-zoster virus (VZV).

263 potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

264 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesv

265 onal and pathogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

266 ia in adults includes common agents, such as varicella-zoster virus and influenza virus, as well as r

267 Varicella-zoster virus antigen was found in 45 of 70 GCA

268 Varicella-zoster virus antigen was frequently found in p

269 e whether herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in tempor

270 gical boosting, through which reexposures to varicella-zoster virus are thought to reduce the individ

271 clonal antibodies against a major antigen of varicella-zoster virus called gE.

272 ES by the corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

273 th HSE (p.Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

274 the phenotypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role

275 The varicella-zoster virus geometric mean titer (GMT) and ge

276 ve (at months 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted wi

277 An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vacci

278 ubjects received 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with

279 g older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adju

280 zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with su

281 or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more we

282 erties that may favor reactivation of latent varicella-zoster virus infection.

283 regulate infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, w

284 Available varicella-zoster virus models can be classified in 3 mai

285 -coinfected children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfec

286 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-z

287 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in

288 ty for CMV, EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old c

289 ncing to identify nosocomial transmission of varicella-zoster virus with fatal outcome.

290 2, human herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryp

291 Findings from skin biopsy, viral culture for varicella-zoster virus, and skin prick test to common fo

292 (HSV) and other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navi

293 es (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyss

294 h HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uv

295 in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to va

296 the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA)

297 losely related to herpes simplex viruses and varicella-zoster virus.

298 G synthesis, and elevated antibody titers to varicella-zoster virus.

299 d, for example, in relation to pertussis and varicella-zoster virus.

300 smosis, other infections (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus,